Skip to main content
Back
Watch Compare

Jaguar Health, Inc.

Data quality: 100%
JAGX
Nasdaq Manufacturing Chemicals
$0.38
▼ $0.02 (-5.01%)
Mkt Cap: 4.71 M
Price
$0.38
Mkt Cap
4.71 M
Day Range
$0.37 — $0.40
52-Week Range
$0.31 — $15.48
Volume
655,042
Open $0.40
50D / 200D Avg
$0.58
34.42% below
50D / 200D Avg
$1.52
75.06% below

Quick Summary

Key Takeaways

Negative free cash flow of -23.70 M
Capital efficient — spends only 0.14% of revenue on capex

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)-1.52%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-953.38%
Below sector avg (-51.02%)
ROIC-223.87%
Net Margin-465.42%
Op. Margin-398.82%

Safety

Debt / Equity
N/A
Current Ratio0.81
Interest Coverage-685.19

Valuation

PE (TTM)
-0.09
Above sector avg (-1.98)
P/B Ratio1.08
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (44 peers)
Metric Stock Sector Median
P/E -0.1 -2.0
P/B 1.1 5.1
ROE % -953.4 -51.0
Net Margin % -465.4 -150.2
Rev Growth 5Y % — 9.3
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) -1.52% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 11.51 M Net Income (TTM) -53.58 M
ROE -953.38% ROA -109.63%
Gross Margin N/A Operating Margin -398.82%
Net Margin -465.42% Free Cash Flow (TTM) -23.70 M
ROIC -223.87% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0.81
Interest Coverage -685.19 Asset Turnover 0.24
Working Capital -6.72 M Tangible Book Value -12.93 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.09 Forward P/E N/A
P/B Ratio 1.08 P/S Ratio 0.41
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -503.56%
Market Cap 4.71 M Enterprise Value 1.18 M
Per Share
EPS (Diluted TTM) -22.97 Revenue / Share 0.93
FCF / Share -1.91 OCF / Share -1.91
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0.14% FCF Conversion 44.24%
SBC-Adj. FCF -24.72 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 11.51 M 11.69 M — 11.96 M —
Net Income -53.58 M -38.49 M -41.30 M -48.40 M -52.60 M
EPS (Diluted) -22.97 -130.69 -1.79 -36.18 -1.18
Gross Profit — — — — —
Operating Income -45.91 M -30.83 M -34.29 M -34.42 M -40.71 M
EBITDA — — — — —
R&D Expenses 24.97 M 16.54 M 18.60 M 17.65 M 15.08 M
SG&A Expenses — — — — —
D&A 1.91 M 1.90 M 2.01 M 1.98 M 1.72 M
Interest Expense 67,000.0 231,000.0 6.38 M 12.72 M 8.42 M
Income Tax 0.0 0.0 — 0.0 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 38.32 M 53.43 M 50.76 M 47.45 M 53.27 M
Total Liabilities 57.01 M 44.45 M 45.87 M 48.81 M 41.41 M
Shareholders' Equity -18.69 M 6.49 M 4.90 M -1.36 M 11.85 M
Total Debt — — — — —
Cash & Equivalents 968,000.0 8.00 M 6.47 M 5.47 M —
Current Assets 20.35 M 32.20 M 27.96 M 22.32 M 28.43 M
Current Liabilities 40.65 M 19.70 M 13.99 M 30.34 M 15.47 M